Head and neck squamous cell carcinoma in HIV patients.
Journal
Current opinion in otolaryngology & head and neck surgery
ISSN: 1531-6998
Titre abrégé: Curr Opin Otolaryngol Head Neck Surg
Pays: United States
ID NLM: 9417024
Informations de publication
Date de publication:
01 Apr 2023
01 Apr 2023
Historique:
entrez:
13
3
2023
pubmed:
14
3
2023
medline:
15
3
2023
Statut:
ppublish
Résumé
The introduction of antiretroviral therapy has significantly impacted the incidence of head and neck squamous cell carcinoma (HNSCC) in people living with HIV (PLWH). This manuscript aims to give an overview of the evidence in the literature about this population. PLWH have an increased incidence of HNSCC, with earlier age and more advanced stage at diagnosis. This epidemiologic trend may be explained by combining traditional and HIV-related risk factors. With the improvement of global health status, more patients are candidate for complex therapeutic strategies with curative intent. To date, it is still debated whether HIV-infected patients possess a profile of increased risk regarding treatment-related toxicity and survival outcomes, with the literature still lacking substantial evidence. Among the prognostic factors that can guide the clinician in selecting the most appropriate treatment strategy, age, site/subsite, stage, HIV viral load, and CD4+ T-cell count at diagnosis are the most relevant. Pathogenesis, treatment characteristics, oncologic outcomes, and prognostic factors of HNSCC in PLWH are still debated. Given the increasing incidence of HNSCC in PLWH, the need for dedicated evidence-based studies represents a significant research gap to be addressed.
Identifiants
pubmed: 36912219
doi: 10.1097/MOO.0000000000000868
pii: 00020840-202304000-00004
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
78-82Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853–860.
Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011; 103:753–762.
Palella FJ, Baker RK, Buchacz K, et al. HOPS Investigators. Increased mortality among publicly insured participants in the HIV Outpatient Study despite HAART treatment. AIDS Lond Engl 2011; 25:1865–1876.
Deeken JF, Tjen-A-Looi A, Rudek MA, et al. The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis 2012; 55:1228–1235.
Lifson AR, Lando HA. Smoking and HIV: Prevalence, health risks, and cessation strategies. Curr HIV/AIDS Rep 2012; 9:223–230.
Bedimo RJ, McGinnis KA, Dunlap M, et al. Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr 2009; 52:203–208.
Borsetto D, Fussey J, Fabris L, et al. HCV infection and the risk of head and neck cancer: a meta-analysis. Oral Oncol 2020; 109:104869.
Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirus-associated cancers among persons with AIDS. JNCI J Natl Cancer Inst 2009; 101:1120–1130.
Shiels MS, Copeland G, Goodman MT, et al. Cancer stage at diagnosis in patients infected with the human immunodeficiency virus and transplant recipients. Cancer 2015; 121:2063–2071.
Coghill AE, Han X, Suneja G, et al. Advanced stage at diagnosis and elevated mortality among HIV-infected US cancer patients in the National Cancer Database. Cancer 2019; 125:2868–2876.
Haase K, Piwonski I, Stromberger C, et al. Incidence and survival of HNSCC patients living with HIV compared with HIV-negative HNSCC patients. Eur Arch Otorhinolaryngol 2021; 278:3941–3953.
Rettig EM, Wentz A, Posner MR, et al. Prognostic implication of persistent human papillomavirus type 16 DNA detection in oral rinses for human papillomavirus-related oropharyngeal carcinoma. JAMA Oncol 2015; 1:907–915.
Mazul AL, Hartman CM, Mowery YM, et al. Risk and incidence of head and neck cancers in veterans living with HIV and matched HIV-negative veterans. Cancer 2022; 128:3310–3318.
Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59–67.
Beachler DC, Abraham AG, Silverberg MJ, et al. North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. Incidence and risk factors of HPV-related and HPV-unrelated Head and Neck Squamous Cell Carcinoma in HIV-infected individuals. Oral Oncol 2014; 50:1169–1176.
D'Souza G, Carey TE, William WN, et al. Epidemiology of head and neck squamous cell cancer among HIV-infected patients. J Acquir Immune Defic Syndr 2014; 65:603–610.
Picard A, Arowas L, Piroth L, et al. ORL-HIV-HPV study group. Head and neck squamous cell carcinoma in people living with HIV in France. Med Mal Infect 2018; 48:503–508.
Cutrell J, Bedimo R. Non-aids-defining cancers among HIV-infected patients. Curr HIV/AIDS Rep 2013; 10:207–216.
Suneja G, Lin CC, Simard EP, et al. Disparities in cancer treatment among patients infected with the human immunodeficiency virus. Cancer 2016; 122:2399–2407.
Hernández-Ramírez RU, Shiels MS, Dubrow R, Engels EA. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV 2017; 4:e495–e504.
Douek DC. Disrupting T-cell homeostasis: how HIV-1 infection causes disease. AIDS Rev 2003; 5:172–177.
Dubrow R, Silverberg MJ, Park LS, et al. HIV infection, aging, and immune function: implications for cancer risk and prevention. Curr Opin Oncol 2012; 24:506–516.
Beachler DC, Weber KM, Margolick JB, et al. Risk factors for oral HPV infection among a high prevalence population of HIV-positive and at-risk HIV-negative adults. Cancer Epidemiol Biomark Prev 2012; 21:122–133.
Ceccarelli M, Rullo EV, Facciolà A, et al. Head and neck squamous cell carcinoma and its correlation with human papillomavirus in people living with HIV: a systematic review. Oncotarget 2018; 9:17171–17180.
Tugizov SM, Webster-Cyriaque JY, Syrianen S, et al. Mechanisms of viral infections associated with HIV: workshop 2B. Adv Dent Res 2011; 23:130–136.
Carter MM, Torres SM, Cook DL Jr, et al. Relative mutagenic potencies of several nucleoside analogs, alone or in drug pairs, at the HPRT and TK loci of human TK6 lymphoblastoid cells. Environ Mol Mutagen 2007; 48:239–247.
Krishnan S, Schouten JT, Jacobson DL, et al. ACTG-ALLRT Protocol Team. Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis. Oncology 2011; 80:42–49.
McGinnis GJ, Ning MS, Bvochora-Nsingo M, et al. Management of head and neck cancers with or without comorbid HIV infection in Botswana. Laryngoscope 2021; 131:E1558–E1566.
Sanfilippo NJ, Mitchell J, Grew D, DeLacure M. Toxicity of head-and-neck radiation therapy in human immunodeficiency virus-positive patients. Int J Radiat Oncol Biol Phys 2010; 77:1375–1379.
Powles T, Imami N, Nelson M, et al. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. AIDS 2002; 16:531–536.
Mourad WF, Hu KS, Shasha D, et al. Long-term outcome of seropositive HIV patients with head and neck squamous cell carcinoma treated with radiation therapy and chemotherapy. Anticancer Res 2013; 33:5511–5516.
Walline HM, Carey TE, Goudsmit CM, et al. HNC SPORE HIV supplement consortium. High-risk HPV, biomarkers, and outcome in matched cohorts of head and neck cancer patients positive and negative for HIV. Mol Cancer Res MCR 2017; 15:179–188.
Zhang H, Kim S, Chen Z, et al. Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma. Head Neck 2017; 39:2433–2443.
Grover S, Desir F, Jing Y, et al. Reduced cancer survival among adults with HIV and an AIDS-defining illnesses despite no difference in cancer stage at diagnosis. J Acquir Immune Defic Syndr 2018; 79:421–429.
Mazul AL, Hartman C, Kramer J, et al. Incidence and survival for oropharynx and nonoropharynx head and neck cancers among veterans living with HIV. Cancer Med 2020; 9:9326–9335.
Grew DJ, Cooper BT, Nguy S, et al. Toxicity and disease-related outcomes after radiotherapy for head and neck cancer in human immunodeficiency virus-positive patients. Front Oncol 2014; 4:316.
Picard A, Badoual C, Hourseau M, et al. Human papilloma virus prevalence in HIV patients with head and neck squamous cell carcinoma. AIDS 2016; 30:1257–1266.
Gleber-Netto FO, Rao X, Guo T, et al. Variations in HPV function are associated with survival in squamous cell carcinoma. JCI Insight 2019; 4:e124762.
Serrano-Villar S, Wu K, Hunt PW, et al. Predictive value of CD8+ T cell and CD4/CD8 ratio at two years of successful ART in the risk of AIDS and non-AIDS events. EBioMedicine 2022; 80:104072.
Fischer CA, Kampmann M, Zlobec I, et al. p16 expression in oropharyngeal cancer: its impact on staging and prognosis compared with the conventional clinical staging parameters. Ann Oncol 2010; 21:1961–1966.